Search Results
Your search for ,USE matches 11256 pages
Showing 4051 - 4100Expert Point of View: Thomas J. Herzog, MD, and Kathleen N. Moore, MD
Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PAOLA-1 trial findings along with updated results of the PRIMA trial, called the difference in progression-free survival with the addition of olaparib to bevacizumab “remarkable” after ...
Expert Point of View: Susan Domchek, MD, and Aditya Bardia, MD, MPH
“PARP inhibitors are a major advance in the treatment of BRCA1- and BRCA2-mutated tumors, including prostate, breast, ovarian, and pancreatic cancers,” said discussant Susan Domchek, MD, Director of the Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center in Philadelphia. Nevertheless,...
App Calculates Risk of Delaying Cancer Care During the COVID-19 Pandemic
A team of data scientists and oncologists from the University of Michigan and Pennsylvania State University have developed a free, Web-based application to help in comparing the long-term risk to a patient from a months-long postponement of care to the additional risk posed by potential COVID-19...
Expert Point of View: David G. Huntsman, MD
Study discussant David G. Huntsman, MD, Founder and Chief Medical Officer of Contextual Genomics, noted the positive predictive value of DETECT-A was 19%, which increased to 41% with the addition of positron-emission tomography/computed tomography. He pointed out that most cancers detected by the...
Study Shows Blood Test Can Identify Multiple Cancers in Asymptomatic Women
A large, “first-of-its-kind” trial showed that a blood test could identify cancers in women with no history of cancer and who were asymptomatic. Of about 10,000 women enrolled in the study, 134 had positive results on blood screening; 26 of these women were found to have cancers. Conventional...
AACR Names Barbara J. Wold, PhD, Recipient of Distinguished Lectureship
The American Association for Cancer Research (AACR) announced the awarding of the 2020 AACR–Irving Weinstein Foundation Distinguished Lectureship to Barbara J. Wold, PhD. Dr. Wold was recently appointed as Director of the Merkin Institute for Translational Research at the California Institute of...
New Cancer Cachexia Guideline Addresses Common Quality-of-Life Issue
ASCO recently released a new evidence-based guideline regarding the clinical management of cancer cachexia in adults with advanced cancer.1 The guideline is the result of a literature review that included 20 systematic reviews and 13 randomized clinical trials. An expert panel was convened to...
Expert Point of View: TROPHIMMUN Trial
Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...
The Gambler
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Comprehensive Overview of How to Start or Improve a Breast Cancer Unit on the Global Stage
Breast cancer is the leading cause of cancer death among women worldwide. As populations age, the incidence of cancer inevitably increases—the World Health Organization has predicted a dramatic increase in global breast cancer cases during the next 15 years. Moreover, breast cancer is increasing in ...
Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...
Ibrutinib in Combination With Rituximab in Chronic Lymphocytic Leukemia
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Rates of Testicular Cancer Rising Among Racial/Ethnic Minorities in the United States
Between 2001 and 2016 in the United States, Asian/Pacific Islander men experienced the greatest increase in the incidence of testicular germ cell tumors, followed by Hispanic and American Indian/Alaska Native men, according to a study published by Ghazarian et al in Cancer Epidemiology, Biomarkers...
Outcomes With Minimally Invasive vs Open Esophagectomy in Routine Practice
In a Dutch study reported in the Journal of Clinical Oncology, Markar et al found that routine use of minimally invasive vs open esophagectomy for esophageal cancer was associated with increased risk of pulmonary complications and other adverse outcomes, contrary to the findings of the clinical...
Impact of the COVID-19 Pandemic on Pediatric Cancer Care in Latin America
In a commentary published in The Lancet Oncology, Vasquez et al presented results of a survey of pediatric oncologists/hematologists across Latin America, which showed an adverse early impact of the COVID-19 pandemic on pediatric cancer care. Study Details The study included a cross-sectional...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
PSA Level Prior to Salvage Radiotherapy: Tailoring Delivery of ADT to Men With Prostate Cancer Most Likely to Benefit
In a recent article in JAMA Oncology, reviewed in this issue of The ASCO Post, Dess et al present an important analysis to help guide decision-making in the setting of salvage radiotherapy in prostate cancer.1 This secondary analysis assessed the association of prostate-specific antigen (PSA)...
Addition of CD38-Directed Antibody Isatuximab to Multiple Myeloma Armamentarium
The treatment approaches to multiple myeloma have significantly changed over the past decade with the introduction of many new active agents. Among them, the monoclonal antibodies have been one of the most exciting advances in myeloma, complementing their success in other hematologic cancers. In...
Nivolumab vs Bevacizumab in Recurrent Glioblastoma
As reported in JAMA Oncology by David A. Reardon, MD, and colleagues, the phase III CheckMate 143 trial showed no difference in overall survival among adult patients with a first recurrence of glioblastoma treated with nivolumab vs bevacizumab following standard radiation and temozolomide therapy. ...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial any PSMA-targeted therapy, and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
A Nobel Laureate’s Road to Research Is Not Without Challenges
The 2019 Nobel Prize for Physiology and Medicine was jointly awarded to three researchers. Their discoveries paved the way for promising new strategies to treat anemia, cancer, and many other diseases. One of the three Nobel Laureates is William G. Kaelin, Jr, MD, who continues his research at his...
An Early Interest in Cancer Immunology Inspires a Life’s Work in Melanoma
F. Stephen Hodi, MD, Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, was born in Framingham and grew up in the town of Acton, a western suburb of Boston. “My dad was an engineer, and I was influenced by puzzle-solving and using...
ASCO’s President Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
From the United States to Germany and Back Again to Become ASCO President in 2021–2022
ASCO President-Elect Everett E. Vokes, MD, FASCO, is the John E. Ultmann Professor, Chair of the Department of Medicine, and Physician-in-Chief of University of Chicago Medicine and Biological Sciences. After a journey from the United States to Germany and back again, Dr. Vokes arrived at the...
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program (Abstract 5515) and published in The New England Journal of Medicine, Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT)...
Standard vs Histology-Tailored Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcoma
As reported in the Journal of Clinical Oncology by Alessandro Gronchi, MD, and colleagues, final results of a phase III trial conducted by the Italian, French, and Polish Sarcoma Groups showed no disease-free or overall survival benefit with use of histology-tailored vs standard...
IMvigor130: First-Line Atezolizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs platinum-based chemotherapy alone in patients ...
Tribute to Bernard Fisher, MD
Bernard Fisher, MD, who died on October 16, 2019, at the age of 101, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His...
Renowned Researcher and Surgeon Helps to Transform Treatment of Breast Cancer
Although ‘paradigm shifts’ are frequently referenced in oncology, these are really few and far between. They occur when new data either partially invalidate previously accepted theory or are at complete odds with the existing paradigm. Moving away from the Halsted radical mastectomy, a standard of ...
Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).
Expert in Clinical Trial Methodology Makes His Mark in Genitourinary Cancer
In 2019, at the ASCO Annual Meeting, Ian Tannock, MD, PhD, DSc, FASCO, was honored with the Allen S. Lichter Visionary Award for his contributions to the fields of genitourinary and breast cancers as well as his efforts to optimize clinical trial design. The title of his lecture was “Clinical...
Love of Science, Passion for Research, and Belief in the Power of the Immune System
Steven A. Rosenberg, MD, PhD, FASCO, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that ...
Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim...
Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at the ASCO20 Virtual Scientific Program, including the use of targeted and immunotherapies in earlier lines of therapy, where they have made a...
Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program...
Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers
Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) study provide real-world evidence to support recent clinical trial data that demonstrate a role for olaparib in the treatment of advanced prostate and pancreatic cancers with BRCA1/2-inactivating...
Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
Use of Symptom Assessment Scale vs Routine Management in Patients With Cancer Receiving Radiotherapy
In a single-institution study reported in JCO Oncology Practice, Goyal et al found that use of the Edmonton Symptom Assessment Scale (ESAS) self-assessment tool during weekly on-treatment physician visits was associated with reduced symptom severity vs routine symptom management in patients...
ESMO Breast 2020: Study Finds Physical Activity, Supportive Care to Relieve Cancer-Related Fatigue May Be Underutilized by Breast Cancer Survivors
Cancer-related fatigue is a prevalent and potentially persistent issue among breast cancer survivors. A study presented by Di Meglio et al at the ESMO Breast Cancer Virtual Meeting 2020 (Abstract 183O) has now shown that existing recommendations and proven strategies for reducing fatigue—which can...
ESMO Breast 2020: Patient Preference for Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for HER2-Positive Early Breast Cancer
At the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Meeting 2020, Joyce O’Shaughnessy, MD, of Baylor University Medical Center, reported results from an interim analysis of the PHranceSCa study (Abstract 80O). The study investigators found that over 80% of patients preferred...
New Guidance Released for Oncology Community on Allocation of Limited Resources During the COVID-19 Pandemic
ASCO recently released a set of recommendations to support the oncology community as health-care institutions across the United States face potentially difficult decisions around the allocation of scarce health-care resources during the COVID-19 pandemic. In some geographic areas, the ongoing...
Tips for First-Time Abstract Presenters
The fundamental goal of scientific meetings is to share knowledge and accelerate scientific advances. Investigators use different types of presentations to disseminate and share their valuable work with others in the field. This is an important aspect of promoting their scientific careers. These...
Brain Cancer Prepared Me for the Isolation and Uncertainty of the COVID-19 Pandemic
The symptoms of low-grade oligodendroglioma first appeared in the summer of 2003, when I was 12, but they were vague enough—mild headaches and occasional weird sensations on my right side—to ignore. In the fall, I tripped and fell during a game of rollerblade hockey with my classmates and started...
COVID-19 Evidence Accelerator Leverages Real-World Data
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) in collaboration with Friends of Cancer Research recently announced the COVID-19 Evidence Accelerator, an expansive public-private partnership combining the efforts of academic, government, and private sector organizations...
Artificial Blood Substitute
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Radium Era: 1916–1945 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
